Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- Inqovi (cedazuridine / decitabine)
- levofloxacin
Interactions between your drugs
No drug ⬌ drug interactions were found between the drugs in your list. However, this does not necessarily mean no drug interactions exist. Always consult your healthcare provider.
Drug and food interactions
levoFLOXacin food
Applies to: levofloxacin
ADJUST DOSING INTERVAL: Food may reduce the oral absorption and bioavailability of levofloxacin. According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.
MANAGEMENT: To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals. For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin. The oral tablets may be taken without regard to food.
References (1)
- Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT (2009) "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm, 66, p. 1438-67
cedazuridine food
Applies to: Inqovi (cedazuridine / decitabine)
ADJUST DOSING INTERVAL: There are no data regarding the concurrent administration of oral cedazuridine-decitabine with food.
MANAGEMENT: The manufacturer recommends that patients avoid eating for 2 hours before and 2 hours after administration of oral cedazuridine-decitabine.
References (1)
- (2020) "Product Information. Inqovi (cedazuridine-decitabine)." Taiho Oncology, Inc.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Reblozyl
Reblozyl is used to treat anemia in adults with beta-thalassemia or myelodysplastic syndromes ...
Vidaza
Vidaza is used to treat certain types of bone marrow cancers and blood cell disorders. Learn about ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Tibsovo
Tibsovo (ivosidenib) is a once-daily oral medication that targets a specific gene mutation called ...
Dacogen
Dacogen (decitabine) is used to treat myelodysplastic syndromes (certain types of blood or bone ...
Rytelo
Rytelo (imetelstat) is an injectable telomerase inhibitor that may be used to treat adults with ...
Onureg
Onureg (azacitidine) is used for the continued treatment of adult patients with acute myeloid ...
Decitabine
Decitabine is used for acute myeloid leukemia, myelodysplastic syndrome
Ivosidenib
Ivosidenib is used for acute myeloid leukemia, biliary tract tumor, myelodysplastic syndrome
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.